Rick Doblin (born November 30, 1953) is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS).
|Born||November 30, 1953|
|Alma mater||New College of Florida
Harvard's John F. Kennedy School of Government
|Occupation||Founder and Executive Director, Multidisciplinary Association for Psychedelic Studies (MAPS)|
|Known for||Psychedelic therapy, MAPS|
Life and career
From 1975 until 1982, Doblin owned and operated a company called Braxas Construction, located in the Sarasota, Florida area, which specialized in relocating houses. He received his doctorate in Public Policy from Harvard’s Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master's thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients. He currently resides in Boston with his wife and three children.
Doblin obtained a psychology degree from New College of Florida in 1987 and earned a doctorate in public policy from the Kennedy School of Government, Harvard University in 2001. His undergraduate thesis at New College of Florida was a 25-year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He also conducted a thirty-four year follow-up study to Timothy Leary’s Concord Prison Experiment. Rick studied with Dr. Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner.
He co-founded Earth Metabolic Design Laboratories in 1984 to support psychedelic research and Multidisciplinary Association for Psychedelic Studies (MAPS) in 1986 with the goal of making MDMA an FDA-approved medicine.
Rick Doblin's life is profiled in former Washington Post Magazine editor Tom Shroder's book Acid Test: LSD, Ecstasy, and the Power to Heal.
Multidisciplinary Association for Psychedelic Studies
Rick Doblin, Ph.D., is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS), a non-profit research organization established in 1986. His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist.
- Frith, C.; Chang, L.; Lattin, D.; Walls, R.; Hamm, J.; Doblin, R. (1987). "Toxicity of methylenedioxymethamphetamine (MDMA) in the dog and the rat". Fundamental and Applied Toxicology 9 (1): 110–19. doi:10.1016/0272-0590(87)90158-8.
- Doblin, R. (1991). "Pahnke's "Good Friday Experiment": A long-term follow-up and methodological critique" (PDF). Journal of Transpersonal Psychology 23 (1): 1–28.
- Doblin, R.; Kleiman, M. (May 1, 1991). "Medical use of marijuana". Annals of Internal Medicine 114 (9): 809–10. doi:10.7326/0003-4819-114-9-809_3. PMID 1842667.
- Doblin, R.; Kleiman, M. (July 1991). "Marijuana as antiemetic medicine: a survey of oncologists' experiences and attitudes.". Journal of Clinical Oncology 9 (7): 1314–1319. PMID 2045870.
- Grinspoon, L.; Bakalar, J.; Doblin, R. (1995). "Marijuana, the AIDS wasting syndrome, and the U.S. government". The New England Journal of Medicine 333 (10): 670–1. doi:10.1056/nejm199509073331020. PMID 7637743.
- Doblin, R.; Kleiman, M. (1995). "The medical use of marijuana: the case for clinical trials". Journal of Addictive Diseases 14 (1): 5–14. doi:10.1300/J069v14n01_02. PMID 7543287.
- Doblin, R.; Kleiman, M. (1998). "Survey research vs clinical trials in evaluating the medical utility of marijuana". Southern Medical Journal 91 (10): 989–91. doi:10.1097/00007611-199810000-00032. PMID 9786301.
- Doblin, R. (1998). "Dr. Leary's Concord Prison Experiment" (PDF). Journal of Psychoactive Drugs 30 (4): 419–426. doi:10.1080/02791072.1998.10399715. PMID 9924845.
- Regulation of the Medical Use of Psychedelics and Marijuana . A dissertation by R. Doblin for his Ph.D. in Public Policy from the Kennedy School of Government, Harvard University. June 2002.
- Doblin, R. (Autumn 2002). "A Clinical Plan for MDMA (Ecstasy) in the Treatment of Post-traumatic Stress Disorder (PTSD): Partnering with the FDA" (PDF). MAPS Bulletin 12 (3): 5–18.
- Mithoefer, M.; Jerome, L.; Doblin, R. (2003). "MDMA ('ecstasy') and neurotoxicity". Science 300 (5625): 1504–5. doi:10.1126/science.300.5625.1504. PMID 12791964.
- Summall, H.; Jerome, L.; Doblin, R. (2004). "Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449-450" (PDF). Psychopharmacology 171 (2): 229–30. doi:10.1007/s00213-003-1599-3. PMID 14634709.
- Mithoefer, M.; Wagner, M.; Mithoefer, A.; Jerome, L.; Doblin, R. (2010). "The safety and efficacy of 3,4-methylenedioxymethamphetamine assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study" (PDF). Journal of Psychopharmacology 25 (4): 439–452. doi:10.1177/0269881110378371. PMC 3122379. PMID 20643699.
- Mithoefer, M.; Wagner, M.; Mithoefer, A.; Jerome, L.; Martin, S.; Yazar-Klosinski, B.; Michel, Y.; Brewerton, T.; Doblin, R. (2012). "Durability of improvement in posttraumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study" (PDF). Journal of Psychopharmacology 27 (1): 28–39. doi:10.1177/0269881112456611. PMC 3573678. PMID 23172889.
- Peter, G.; Dominique, H.; Yvonne, M.; R., D.; Berra, Y.-Klosinski; Torsten, P.; Rudolf, B. (2014). "Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases" (PDF). The Journal of Nervous and Mental Disease 202 (7): 513–20. doi:10.1097/NMD.0000000000000113. PMID 24594678.
- The MAPS Staff
- Erowid character vaults
- Miliard, Mike: This is your brain on drugs: Rick Doblin thinks pot, ecstasy, and other psychedelics could unlock the human mind — and he wants to bring them to Harvard, the FDA, and a doctor’s office near you, The Boston Phoenix, Oct. 8-14, 2004.
- Cox, Billy (14 August 2008). "Had a nice trip. Wish you could, too.". Herald Tribune. Retrieved 2 November 2012.
- Rick Doblin discusses the current state of research on MDMA (aka 'Ecstasy') and the possible benefits
- An interview with Rick Doblin features information about his background and career
|This Hallucinogen-related article is a stub. You can help Wikipedia by expanding it.|